

# Raiffeisen-Health and Wellbeing-ESG-Equities

(Original German name: Raiffeisen-Health and Wellbeing-ESG-Aktien)

## **semi-annual fund report**

reporting period Jun 1, 2022 – Nov 30, 2022

## Table of contents

General fund information .....	3
Fund characteristics.....	3
Legal notice .....	4
Fund details.....	5
Units in circulation.....	5
Fund investment policy report .....	6
Makeup of fund assets in EUR .....	7
Portfolio of investments in EUR as of Nov 30, 2022.....	8
Appendix .....	13

# Report for the reporting period from Jun 1, 2022 to Nov 30, 2022

## General fund information

ISIN	Tranche	Income class	Currency	Launch date
AT0000714274	Raiffeisen-Health and Wellbeing-ESG-Equities (R) A	income-distributing	EUR	Apr 18, 2001
AT0000A1U651	Raiffeisen-Health and Wellbeing-ESG-Equities (RZ) A	income-distributing	EUR	Apr 3, 2017
AT0000714282	Raiffeisen-Health and Wellbeing-ESG-Equities (R) T	income-retaining	EUR	Apr 18, 2001
AT0000A1U644	Raiffeisen-Health and Wellbeing-ESG-Equities (RZ) T	income-retaining	EUR	Apr 3, 2017
AT0000A2XN33	Raiffeisen-Health and Wellbeing-ESG-Aktien (SZ) T <sup>1</sup>	income-retaining	EUR	Jun 1, 2022
AT0000A2R8Q2	Raiffeisen-Health and Wellbeing-ESG-Equities (I) VTA	full income-retaining (outside Austria)	EUR	Jun 1, 2021
AT0000712716	Raiffeisen-Health and Wellbeing-ESG-Equities (R) VTA	full income-retaining (outside Austria)	EUR	Oct 29, 2002

<sup>1</sup> Tranche SZ is exclusively for investments within the scope of the Raiffeisen Banking Group's sustainable asset management.

## Fund characteristics

Fund currency	EUR
Financial year	Jun 1 – May 31
Distribution/payment/reinvestment date	Aug 16
Type of fund	Investment fund pursuant to § 2 of the Austrian Investment Fund Act, InvFG (UCITS)
Effective management fee for the fund	I-Tranche (EUR): 1.000 % R-Tranche (EUR): 2.000 % RZ-Tranche (EUR): 1.000 % SZ-Tranche (EUR): 0.650 %
Custodian bank	Raiffeisen Bank International AG
Management company	Raiffeisen Kapitalanlage-Gesellschaft m.b.H. Mooslackengasse 12, A-1190 Vienna Tel. +43 1 71170-0 Fax +43 1 71170-761092 www.rcm.at Companies register number: 83517 w
Fund management	Raiffeisen Kapitalanlage-Gesellschaft m.b.H.
Auditor	KPMG Austria GmbH

The fund is actively managed without reference to a benchmark.

### **Legal notice**

The software used performs calculations on the basis of more than the two decimal places displayed. Minor discrepancies cannot be ruled out due to further calculations using published results.

The value of a unit is calculated by dividing the entire value of the investment fund inclusive of its income by the number of units. The total value of the investment fund is calculated on the basis of the current market prices of the securities, money market instruments and subscription rights in the fund plus the value of the fund's financial investments, cash holdings, credit balances, receivables and other rights net of its payables. That value will be calculated by the custodian bank.

The net assets are calculated in accordance with the following principles:

- a) The value of assets quoted or traded on a stock exchange or other regulated market shall be determined, in principle, on the basis of the most recently available price.
- b) Where an asset is not quoted or traded on a stock market or another regulated market or where the price for an asset quoted or traded on a stock market or another regulated market does not appropriately reflect its actual market value, the prices provided by reliable data providers or, alternatively, market prices for equivalent securities or other recognized market valuation methods shall be used.

Raiffeisen KAG calculates performance based on the published fund price, using the OeKB methodology. Individual costs – such as transaction fees, the subscription fee (not exceeding 0.00 %), the redemption fee (not exceeding 0.00 %) or custody charges of the investor – and taxes are not included in the performance calculation. These would reduce the performance if they were included. Past value is not a reliable indicator of the fund's future performance.

Dear unitholder,

Raiffeisen Kapitalanlage-Gesellschaft m.b.H. is pleased to present its semi-annual fund report for Raiffeisen-Health and Wellbeing-ESG-Equities for the reporting period from Jun 1, 2022 to Nov 30, 2022. The accounting is based on the price calculation as of Nov 30, 2022.

## Fund details

	May 31, 2022	Nov 30, 2022
Total fund assets in EUR	192,101,835.70	205,308,940.30
Net asset value/distributing units (R) (AT0000714274) in EUR	236.81	239.87
Issue price/distributing units (R) (AT0000714274) in EUR	236.81	239.87
Net asset value/distributing units (RZ) (AT0000A1U651) in EUR	142.05	144.60
Issue price/distributing units (RZ) (AT0000A1U651) in EUR	142.05	144.60
Net asset value/reinvested units (R) (AT0000714282) in EUR	287.01	294.18
Issue price/reinvested units (R) (AT0000714282) in EUR	287.01	294.18
Net asset value/reinvested units (RZ) (AT0000A1U644) in EUR	150.97	155.28
Issue price/reinvested units (RZ) (AT0000A1U644) in EUR	150.97	155.28
Net asset value/reinvested units (SZ) (AT0000A2XN33) in EUR	-	103.69
Issue price/reinvested units (SZ) (AT0000A2XN33) in EUR	-	103.69
Net asset value/fully reinvested units (I) (AT0000A2R8Q2) in EUR	110.99	114.84
Issue price/fully reinvested units (I) (AT0000A2R8Q2) in EUR	110.99	114.84
Net asset value/fully reinvested units (R) (AT0000712716) in EUR	302.01	310.93
Issue price/fully reinvested units (R) (AT0000712716) in EUR	302.01	310.93

## Units in circulation

	Units in circulation on May 31, 2022	Sales	Repurchases	Units in circulation on Nov 30, 2022
AT0000714274 (R) A	66,716.089	3,167.428	-787.671	69,095.846
AT0000A1U651 (RZ) A	37,103.311	2,233.875	-897.096	38,440.090
AT0000714282 (R) T	324,289.992	39,546.374	-24,655.911	339,180.455
AT0000A1U644 (RZ) T	201,654.900	24,033.521	-9,685.755	216,002.666
AT0000A2XN33 (SZ) T	-	10.000	0.000	10.000
AT0000A2R8Q2 (I) VTA	10.000	0.000	0.000	10.000
AT0000712716 (R) VTA	157,315.857	23,580.127	-20,575.947	160,320.037
<b>Total units in circulation</b>				<b>823,059.094</b>

## Fund investment policy report

In the period under review, the fund gained 4.72 %. The stock markets were extremely upbeat in the first month of the reporting period and were well supported by excellent economic data, not least due to a very satisfactory reporting season. Between mid-August 2022 and mid-October 2022, fears of a sharp slowdown in growth, which had been simmering in the context of almost all-time high inflation figures, intensified at the global level. Growing numbers of macroeconomists were painting an ever more downbeat picture – both for 2023 and 2024. Rising fears of recession sent the major stock indexes plummeting to new lows for the year. Delivering the second best performance of all MSCI sector indexes, the health sector clearly proved its defensive qualities during the period under review. Especially large pharmaceutical companies posted significant gains in the double-digit percentage range. Even the “Inflation Reduction Act of 2022” passed by the US Congress at the beginning of August 2022, which may have a negative impact on some pharmaceutical companies from 2025 onwards, did nothing to prevent this trend. However, as yet there is little solid information as to the drugs, treatments and manufacturers that will be affected, nor as to the likely extent (in terms of rebates). Between June 2022 and November 2022, the biotechnology sector recovered substantially despite the rise in interest rates, which generally have a negative effect on companies in this industry (before they are profitable, many companies require annual financing rounds). Since early autumn, M&A activity among biotech companies has picked up significantly. At the end of November 2022, for example, the Horizon Therapeutics share, which had only been added to the fund in early July 2022, turned into a takeover target for a group of three companies. At the time of reporting, a decision has probably been made in favor of Amgen as the buyer. The medical technology sector continued to suffer from the widespread disruption caused by COVID-19 (fewer operations and doctor’s visits, persistent supply chain impairments). The well-being segment (water treatment, hygiene, safety technology, sporting goods and health food) is covered by industry, defensive and cyclical consumption and utilities. In this area, the individual sectors recorded a similar development. During the second half of the financial year, the fund purchased the shares of Horizon Therapeutics (biotechnology with a focus on inflammatory and rare diseases), Tandem Diabetes (insulin infusion therapy) and Grifols (blood plasma collection and production of essential drugs). In return, the shares of Suzuken, GN Store Nord, Philips and Haleon were sold. On the reporting date, the biggest exposure in terms of countries was in the USA, followed by Switzerland and Japan.

## Makeup of fund assets in EUR

Any discrepancies in terms of the market value or the share of the fund assets result from rounding-off.

**UCITS** refers to units in an undertaking for collective investment in transferable securities

**§ 166 InvFG** refers to units in investment funds in the form of “other portfolios of assets”

**§ 166 (1) item 2 InvFG** refers to units in special funds

**§ 166 (1) item 3 InvFG** refers to units in undertakings for collective investment in transferable securities pursuant to § 166 (1) item 3 InvFG  
(such as alternative investments/hedge funds)

**§ 166 (1) item 4 InvFG** refers to units in real estate funds

Type of security	OGAW/§ 166	Currency	Market value in EUR	Share of fund assets
Equities		AUD	3,977,684.91	1.94 %
Equities		CHF	15,122,618.49	7.37 %
Equities		DKK	8,487,192.48	4.13 %
Equities		EUR	14,769,499.00	7.19 %
Equities		GBP	11,783,143.14	5.74 %
Equities		HKD	301,646.07	0.15 %
Equities		JPY	8,055,979.74	3.92 %
Equities		NZD	820,848.08	0.40 %
Equities		SEK	4,810,330.14	2.34 %
Equities		USD	132,448,526.41	64.51 %
<b>Total Equities</b>			<b>200,577,468.46</b>	<b>97.70 %</b>
Equities ADR		USD	1,263,824.65	0.62 %
<b>Total Equities ADR</b>			<b>1,263,824.65</b>	<b>0.62 %</b>
<b>Total securities</b>			<b>201,841,293.11</b>	<b>98.31 %</b>
<b>Bank balances/liabilities</b>				
Bank balances/liabilities in fund currency			3,688,682.79	1.80 %
<b>Total bank balances/liabilities</b>			<b>3,688,682.79</b>	<b>1.80 %</b>
<b>Accruals and deferrals</b>				
Interest claims (on securities and bank balances)			10,762.89	0.01 %
Dividends receivable			139,782.06	0.07 %
<b>Total accruals and deferrals</b>			<b>150,544.95</b>	<b>0.07 %</b>
<b>Other items</b>				
Various fees			-371,580.55	-0.18 %
<b>Total other items</b>			<b>-371,580.55</b>	<b>-0.18 %</b>
<b>Total fund assets</b>			<b>205,308,940.30</b>	<b>100.00 %</b>

## Portfolio of investments in EUR as of Nov 30, 2022

Dates indicated for securities refer to the issue and redemption dates. An issuer's right of premature redemption (where applicable) is not specified. The securities marked with a "y" have an open-ended maturity (is perpetual). The price for forward exchange transactions is indicated in the relevant counter currency for the currency in question.

Any discrepancies in terms of the market value or the share of the fund assets result from rounding-off.

**UCITS** refers to units in an undertaking for collective investment in transferable securities

**§ 166 InvFG** refers to units in investment funds in the form of "other portfolios of assets"

**§ 166 (1) item 2 InvFG** refers to units in special funds

**§ 166 (1) item 3 InvFG** refers to units in undertakings for collective investment in transferable securities pursuant to § 166 (1) item 3 InvFG (such as alternative investments/hedge funds)

**§ 166 (1) item 4 InvFG** refers to units in real estate funds

Type of security	OGAW/§ 166	ISIN	Security title	Currency	Volume Units/Nom.	Purchases In period under review Units/Nom.	Sales Units/Nom.	Pool-/ILB Factor	Price	Market value in EUR	Share of fund assets
Equities		AU000000CGC2	COSTA GROUP HOLDINGS LTD CGC	AUD	950,000				2,640,000	1,625,036.45	0.79 %
Equities		AU000000CSL8	CSL LTD CSL	AUD	12,000				302,580,000	2,352,648.46	1.15 %
Equities		CH0432492467	ALCON INC ALC	CHF	28,000				64,160,000	1,823,282.25	0.89 %
Equities		CH0030170408	GEBERT AG-REG GEBN	CHF	5,300				445,600,000	2,396,914.65	1.17 %
Equities		CH0013841017	LONZA GROUP AG-REG LONN	CHF	3,900				486,300,000	1,924,865.52	0.94 %
Equities		CH0012032048	ROCHE HOLDING AG-GENUSSCHEIN ROG	CHF	23,912	1,812			309,250,000	7,505,111.13	3.66 %
Equities		CH0012549785	SONOVA HOLDING AG-REG SOON	CHF	6,000				241,800,000	1,472,444.94	0.72 %
Equities		DK0010272202	GENMAB A/S GWAB	DKK	3,246	246			3,180,000,000	1,388,028.21	0.68 %
Equities		DK0060534915	NOVO NORDISK A/S-B NOVOB	DKK	60,000	8,000			879,900,000	7,099,164.27	3.46 %
Equities		FR0000121667	ESSILORLUXOTTICA EL	EUR	10,000				175,500,000	1,755,000.00	0.85 %
Equities		DE0005664809	EVOTEC SE EVT	EUR	45,800				16,455,000	753,639.00	0.37 %
Equities		ES0171996095	GRIFOLS SA - B GRF/P	EUR	120,000	120,000			7,405,000	888,600.00	0.43 %
Equities		DE0006599905	MERCK KGAA MRK	EUR	15,000				172,100,000	2,581,500.00	1.26 %
Equities		NL0012169213	GIAGEN N.V. GIA	EUR	20,000				47,180,000	943,600.00	0.46 %
Equities		FR0000120578	SANOFL SAN	EUR	46,000	4,000			88,190,000	4,056,740.00	1.98 %
Equities		FR0013154002	SARTORIUS STEDIM BIOTECH DIM	EUR	3,000				315,700,000	947,100.00	0.46 %
Equities		IT0005162406	TECHNOGYM SPA TGYM	EUR	200,000				7,270,000	1,454,000.00	0.71 %
Equities		F0009002158	UPONOR OYJ UPONOR	EUR	94,000				14,780,000	1,389,320.00	0.68 %
Equities		G8000895292	ASTRAZENECA PLC AZN	GBP	51,000				110,600,000	6,535,658.42	3.18 %
Equities		G800BN7SWP63	GSK PLC GSK	GBP	160,223	160,223			14,178,000	2,632,109.02	1.28 %
Equities		G800B39J2M42	UNITED UTILITIES GROUP PLC UJ/	GBP	220,000				10,260,000	2,615,375.70	1.27 %
Equities		BM/G017IK1018	ALIBABA HEALTH INFORMATION T 241	HKD	400,000				6,100,000	301,646.07	0.15 %
Equities		JP3942400007	ASTELLAS PHARMA INC 4503	JPY	85,700	30,000			2,128,500,000	1,273,329.34	0.62 %
Equities		JP3475350009	DAIICHI SANKYO CO LTD 4568	JPY	88,000	5,000			4,536,000,000	2,786,390.55	1.36 %
Equities		JP3270000007	KURITA WATER INDUSTRIES LTD 6370	JPY	53,000				6,170,000,000	2,282,691.93	1.11 %
Equities		JP3347200002	SHIONOGI & CO LTD 4507	JPY	18,100				6,994,000,000	863,670.74	0.43 %
Equities		JP3351100007	SYSMEX CORP 6869	JPY	14,000				8,492,000,000	829,897.18	0.40 %
Equities		NZFAP00001S2	FISHER & PAYKEL HEALTHCARE C FPH	NZD	60,000				22,810,000	820,848.08	0.40 %
Equities		SE0000382335	AUTOLIV INC-SWED DEP RECEIPT ALIV	SEK	24,000				911,600,000	2,003,608.22	0.98 %



Type of security	OGAW/\$ 166	ISIN	Security title	Currency	Volume Units/Nom.	Purchases In period under review Units/Nom.	Sales Units/Nom.	Pool-/ILB Factor	Price	Market value in EUR	Share of fund assets
Equities		SE0009922164	ESSITY AKTIEBLAG-B ESSITYB	SEK	120.000		20.000		255.400000	2.806.721.92	1.37 %
Equities		US0028241000	ABBOTT LABORATORIES ABT	USD	64.700	4.900			105.000000	6.559.648.53	3.20 %
Equities		US00287Y1091	ABBVIE INC ABBV	USD	37.342	1.000			158.200000	5.704.151.40	2.78 %
Equities		US00404A1097	ACADIA HEALTHCARE CO INC ACHC	USD	32.500	2.500			86.020000	2.689.415.83	1.31 %
Equities		US00846U1016	AGILENT TECHNOLOGIES INC A	USD	17.500	1.300			150.940000	2.521.374.98	1.23 %
Equities		US0162551016	ALIGN TECHNOLOGY INC ALGN	USD	6.000				191.830000	1.111.360.02	0.54 %
Equities		US0304201033	AMERICAN WATER WORKS CO INC AMWK	USD	21.000				147.140000	2.983.575.53	1.45 %
Equities		US03073E1055	AMERSOURCEBERGEN CORP ABC	USD	10.000				167.900000	1.621.204.07	0.79 %
Equities		US0311621009	AMGEN INC AMGN	USD	22.500				281.990000	6.126.369.91	2.98 %
Equities		US0718131099	BAXTER INTERNATIONAL INC BAX	USD	29.500				55.340000	1.576.333.70	0.77 %
Equities		US0758871091	BECTON DICKINSON AND CO BDX	USD	10.000				241.020000	2.327.234.10	1.13 %
Equities		US09061G1013	BIOMARIN PHARMACEUTICAL INC BMRN	USD	17.400				97.120000	1.631.717.28	0.79 %
Equities		US11011371077	BOSTON SCIENTIFIC CORP BSX	USD	68.900	5.200			44.500000	2.956.211.08	1.44 %
Equities		US1101221083	BRISTOL-MYERS SQUIBB CO BMY	USD	92.000	4.000			79.030000	7.020.479.89	3.42 %
Equities		US15135B1017	CENTENE CORP CNC	USD	22.000				84.420000	1.793.308.55	0.87 %
Equities		US1255231003	CIGNA CORP CI	USD	14.000				320.700000	4.335.248.39	2.11 %
Equities		US2168484020	COOPER COS INC/THE COO	USD	4.200				307.440000	1.246.799.59	0.61 %
Equities		US2358511028	DANAHER CORP DHR	USD	17.900	1.400			259.020000	4.476.858.01	2.18 %
Equities		US2521311074	DEXCOM INC DXCM	USD	20.000	20.000	5.000		110.390000	2.131.801.28	1.04 %
Equities		US28176E1062	EDWARDS LIFESCIENCES CORP EW	USD	25.500				74.850000	1.842.973.01	0.90 %
Equities		US5245711083	ELI LILLY & CO LLY	USD	29.000				363.950000	10.191.232.56	4.96 %
Equities		US3755581036	GILEAD SCIENCES INC GILD	USD	36.500	8.500			85.760000	3.022.488.29	1.47 %
Equities		US4052171000	HAIN CELESTIAL GROUP INC HAIN	USD	78.000				18.680000	1.406.884.57	0.69 %
Equities		IE00BQPVOZ61	HORIZON THERAPEUTICS PLC HZNP	USD	12.200	12.200			78.760000	927.796.07	0.45 %
Equities		US4448591028	HUMANA INC HUM	USD	6.000				533.140000	3.088.726.89	1.50 %
Equities		US46120E6023	INTUITIVE SURGICAL INC ISRG	USD	14.400				258.800000	3.598.435.76	1.75 %
Equities		US46266C1053	IOVIA HOLDINGS INC IOV	USD	9.200				212.500000	1.887.703.37	0.92 %
Equities		IE00B4Q5ZM47	JAZZ PHARMACEUTICALS PLC JAZZ	USD	11.000				155.650000	1.653.212.96	0.81 %
Equities		US05040R4092	LABORATORY CRP OF AMER HLDGS LH	USD	7.000				239.780000	1.620.682.66	0.79 %
Equities		IE00BTN1Y115	MEDTRONIC PLC MDT	USD	20.300				76.480000	1.499.101.05	0.73 %
Equities		US58933Y1055	MERCK & CO. INC. MRK	USD	85.600				108.840000	8.995.996.72	4.38 %
Equities		US60770K1079	MODERNA INC MRNA	USD	5.000				173.150000	835.948.44	0.41 %
Equities		US5534981064	MSA SAFETY INC MSA	USD	18.400	1.400			136.540000	2.425.854.29	1.18 %
Equities		US2197981051	GUIDELOR THO CORP QDEL	USD	8.000	8.000			83.320000	643.615.12	0.31 %
Equities		US7611521078	RESMED INC RMD	USD	4.700				223.200000	1.012.929.08	0.49 %
Equities		IE00BFY6C754	STERIS PLC STE	USD	9.000				178.390000	1.550.243.81	0.76 %
Equities		US8636671013	STRYKER CORP SYK	USD	11.000				227.200000	2.413.170.47	1.18 %
Equities		US8753722037	TANDEM DIABETES CARE INC TNDM	USD	26.700	26.700			39.940000	1.029.689.57	0.50 %
Equities		US8835561023	THERMO FISHER SCIENTIFIC INC TMO	USD	14.100	1.100			539.750000	7.348.500.94	3.58 %
Equities		US91324P1021	UNITEDHEALTH GROUP INC UNH	USD	19.000				528.000000	9.686.670.21	4.72 %
Equities		US92532F1003	VERTEX PHARMACEUTICALS INC VRTX	USD	12.500				316.330000	3.818.012.84	1.86 %
Equities		US9418481035	WATERS CORP WAT	USD	6.200				330.160000	1.976.528.75	0.96 %
Equities		US98956P1021	ZIMMER BIOMET HOLDINGS INC ZBH	USD	10.000				119.000000	1.149.036.84	0.56 %
Equities ADR		US09075V1026	BIONTECH SE-ADR BNTX	USD	8.000				163.610000	1.263.824.65	0.62 %
<b>Total licensed securities admitted to trading on the official market or another regulated market</b>										<b>201,841,293.11</b>	<b>98.31 %</b>
<b>Total securities</b>										<b>201,841,293.11</b>	<b>98.31 %</b>

Type of security	OGAW/§ 166	ISIN	Security title	Currency	Volume Units/Nom.	Purchases in period under review Units/Nom.	Sales in period under review Units/Nom.	Pool-/ILB Factor	Price	Market value in EUR	Share of fund assets
<b>Bank balances/liabilities</b>											
<b>Total bank balances/liabilities</b>				EUR						3,688,682.79	1.80 %
<b>Accruals and deferrals</b>										<b>3,688,682.79</b>	<b>1.80 %</b>
Interest claims (on securities and bank balances)										10,762.89	0.01 %
Dividends receivable										139,782.06	0.07 %
<b>Total accruals and deferrals</b>										<b>150,544.95</b>	<b>0.07 %</b>
<b>Other items</b>											
Various fees										-371,580.55	-0.18 %
<b>Total other items</b>										<b>-371,580.55</b>	<b>-0.18 %</b>
<b>Total fund assets</b>										<b>205,308,940.30</b>	<b>100.00 %</b>

ISIN	Income class	Currency	Net asset value per unit	Units in circulation
AT0000714274	R	EUR	239.87	69,095,846
AT0000A1U651	RZ	EUR	144.60	38,440,090
AT0000714282	R	EUR	294.18	339,180,455
AT0000A1U644	RZ	EUR	155.28	216,002,666
AT0000A2XN33	SZ	EUR	103.69	10,000
AT0000A2R8Q2	I	EUR	114.84	10,000
AT0000712716	R	EUR	310.93	160,320,037

**Exchange rates**

Foreign currency assets were converted into EUR on the basis of the exchange rates applicable on Nov 29, 2022

Currency	Price (1 EUR =)
Australian Dollars	1.543350
Swiss Francs	0.985300
Danish Kroner	7.436650
British Pound	0.863050
Hong Kong Dollars	8.088950
Japanese Yen	143.256300
New Zealand Dollars	1.667300
Swedish Krona	10.919500
US Dollars	1.036650

**Securities purchases and sales during the period under review not listed under the portfolio of assets:**

Type of security	OGAW/s 166	ISIN	Security title	Currency	Purchases Additions	Sales Disposals
Equities		DK0010272632	GN STORE NORD A/S GN	DKK		32,000
Equities		FR0014008YX5	EUROAPI SASU EAPI	EUR		1,826
Equities		NL0000009538	KONINKLIJKE PHILIPS NV PHIA	EUR		43,567
Equities		GB0009252882	GSK PLC GSK	GBP		185,100
Equities		GB00BWX86B70	HALEON PLC HLN	GBP	185,100	185,100
Equities		JP3398000004	SUZUKEN CO LTD 9987	JPY		5,590
Equities		US2681582019	DYNAVAX TECHNOLOGIES CORP DVAX	USD		13,370
Equities		US4523271090	ILLUMINA INC ILMN	USD		2,500
Equities		US68622Y1061	ORGANON & CO OGN	USD		6,160
Equities		US74838J1016	QUIDELORTHO CORP 9990527D	USD		8,000
Equities		US92556V1061	VIATRIS INC VTRS	USD		10,547
Equities		US98888T1079	ZIMVIE INC ZIMV	USD		1,000
Subscription rights		FR0014009LO3	ESSILORLUXOTTICA SA-SCRIP 2067556D	EUR	10,000	10,000
Subscription rights		NL0015000VF4	KONINKLIJKE PHILIPS-SCRIP 2023252D	EUR		43,567

### Information on securities lending transactions and repurchase agreements

During the reporting period, no securities lending transactions were performed on behalf of the fund. Accordingly, the information concerning securities lending transactions which is stipulated in § 8 of the Austrian Securities Lending and Repurchase Agreement Ordinance and Art. 13 of Regulation (EU) No. 2015/2365 is not required.

During the reporting period, no repurchase agreements were concluded on behalf of the fund. Accordingly, the information concerning repurchase agreements which is stipulated in § 8 of the Austrian Securities Lending and Repurchase Agreement Ordinance and Art. 13 of Regulation (EU) No. 2015/2365 is not required.

### Total return swaps and similar derivative instruments

A total return swap is a credit derivative instrument. Income and fluctuations in the value of the underlying financial instrument (underlying instrument or reference asset) are exchanged for fixed interest payments.

The fund did not enter into total return swaps or similar derivative instruments in the period under review.


**Raiffeisen Kapitalanlage-Gesellschaft m.b.H. complies with the code of conduct for the Austrian investment fund industry 2012.**

Vienna, 24 January 2023

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.



Mag. (FH) Dieter Aigner



Ing. Michal Kustra

## Appendix

### Imprint

Publisher:

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.

Mooslackengasse 12, A-1190 Vienna

Responsible for contents:

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.

Mooslackengasse 12, A-1190 Vienna

Copyright by publisher, dispatch location: Vienna

**Raiffeisen Capital Management** is the brand of:

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.

Raiffeisen Immobilien Kapitalanlage-Gesellschaft m.b.H.

Raiffeisen Salzburg Invest GmbH